Skip to main content

Table 1 Patients’ baseline characteristics according to age

From: Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study results

Characteristic

Age <70 years (n = 1297)

Age ≥70 years (n = 480)

Age <75 years (n = 1571)

Age ≥75 years (n = 206)

Gender, n (%)

    

 Male

811 (63)

297 (62)

985 (63)

123 (60)

 Female

486 (37)

183 (38)

586 (37)

83 (40)

Median age, years (range)

61 (19–69)

73 (70–100)

63 (19–74)

77 (75–100)

ECOG performance status, n (%)

    

 0

503 (39)

153 (32)

598 (38)

58 (28)

 1

647 (50)

251 (52)

785 (50)

113 (55)

 2

119 (9)

56 (12)

147 (9)

28 (14)

 3

4 (<1)

11 (2)

11 (1)

4 (2)

 4

0

1 (<1)

1 (<1)

0

 Missing

24 (2)

8 (2)

29 (2)

3 (1)

Metastatic site, n (%) a

    

 Liver

935 (72)

332 (69)

1130 (72)

137 (67)

 Lung

357 (28)

133 (28)

434 (28)

56 (27)

 Bone

47 (4)

10 (2)

53 (3)

4 (2)

 Other

350 (27)

107 (22)

408 (26)

49 (24)

No. of metastatic sites, n (%)

    

 1

824 (64)

321 (67)

1007 (64)

138 (67)

 >1

405 (31)

124 (26)

476 (30)

53 (26)

 Missing

68 (5)

35 (7)

88 (6)

15 (7)

Local recurrence, n (%)

585 (51)

220 (51)

711 (51)

94 (50)

Median CEA, ng/mL (range)

20.9 (0–14 671)

20.7 (0.1–25305)

20.4 (0–25 305)

25.6 (0.1–6848)

Surgical removal of primary tumour, n (%)

1210 (93)

442 (92)

1464 (93)

188 (91)

Prior radiotherapy, %

18

14

18

12

Prior chemotherapy, %

    

Adjuvant

67

68

67

66

Neoadjuvant

11

11

10

12

Systolic hypertension, %

    

Mild

26

28

27

25

Moderate

6

8

6

10

Severe

1

1

1

1

Diaystolic hypertension, %

    

Mild

17

14

17

12

Moderate

2

3

2

3

Severe

1

1

1

0

  1. CEA, carcinoembryonic antigen; ECOG, Eastern Cooperative Oncology Group. aPatients could have >1 metastatic site.